Literature DB >> 28975992

Association between H19 polymorphisms and osteosarcoma risk.

T-D He1, D Xu, T Sui, J-K Zhu, Z-X Wei, Y-M Wang.   

Abstract

OBJECTIVE: The long non-coding RNA (lncRNA) H19, a maternally expressed imprinted gene, has involvement in cancer susceptibility and disease progression. However, the association between H19 polymorphisms and osteosarcoma susceptibility has remained elusive. We designed this case-control study to explore the association between H19 polymorphism and osteosarcoma risk. PATIENTS AND METHODS: In this study, we genotyped 4 tagger SNPs of the H19 gene in a case-control study including 193 osteosarcoma cases and 393 cancer-free controls.
RESULTS: For the main effect analysis, rs217727 (G>A) was associated with osteosarcoma risk (GA/GG: adjusted OR = 1.51, 95% CI: 1.06-2.17, p = 0.024; AA/GG: adjusted OR = 1.89, 95% CI: 1.23-2.91, p = 0.004; additive model: adjusted OR = 1.35, 95% CI: 1.01-1.80, p = 0.043).
CONCLUSIONS: This finding indicates that rs217727 polymorphism may play a role in genetic susceptibility to the risk of osteosarcoma, which may improve our understanding of the potential contribution of H19 SNPs to cancer pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28975992

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  Tudor-staphylococcal nuclease regulates the expression and biological function of alkylglycerone phosphate synthase via nuclear factor-κB and microRNA-127 in human glioma U87MG cells.

Authors:  Yongqiang Zhang; Jun Jia; Ying Li; Yan-Ge Chen; Huan Huang; Yang Qiao; Yu Zhu
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

2.  Long Noncoding RNA HCG9 Promotes Osteosarcoma Progression through RAD51 by Acting as a ceRNA of miR-34b-3p.

Authors:  Lu Wang; ShuangQing Li; Lin Qi; Lin Ling
Journal:  Mediators Inflamm       Date:  2021-08-18       Impact factor: 4.529

Review 3.  SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?

Authors:  Linda Minotti; Chiara Agnoletto; Federica Baldassari; Fabio Corrà; Stefano Volinia
Journal:  High Throughput       Date:  2018-11-16

4.  Associations between H19 polymorphisms and neuroblastoma risk in Chinese children.

Authors:  Chao Hu; Tianyou Yang; Jing Pan; Jiao Zhang; Jiliang Yang; Jing He; Yan Zou
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

5.  The long non coding RNA H19 as a biomarker for breast cancer diagnosis in Lebanese women.

Authors:  Tamina Elias-Rizk; Joelle El Hajj; Evelyne Segal-Bendirdjian; George Hilal
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

6.  Associations of lncRNA H19 Polymorphisms at MicroRNA Binding Sites with Glioma Susceptibility and Prognosis.

Authors:  Yujiao Deng; Linghui Zhou; Jia Yao; Yu Liu; Yi Zheng; Si Yang; Ying Wu; Na Li; Peng Xu; Lijuan Lyu; Dai Zhang; Jun Lyu; Zhijun Dai
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-13       Impact factor: 8.886

7.  Association between lncRNA H19 rs217727 polymorphism and the risk of cancer: an updated meta-analysis.

Authors:  Xue Wang; Jialing Zhong; Fang Chen; Kang Hu; Suhong Sun; Yuanxiu Leng; Xumei Chen; Fengjiao Gan; Yana Pan; Qing Luo
Journal:  BMC Med Genet       Date:  2019-11-21       Impact factor: 2.103

8.  Association between lncRNA-H19 polymorphisms and hepatoblastoma risk in an ethic Chinese population.

Authors:  Tianbao Tan; Jiahao Li; Yang Wen; Yan Zou; Jiliang Yang; Jing Pan; Chao Hu; Yuxiao Yao; Jiao Zhang; Yijuan Xin; Suhong Li; Huimin Xia; Jing He; Tianyou Yang
Journal:  J Cell Mol Med       Date:  2020-11-24       Impact factor: 5.295

9.  Significant association between long non-coding RNA H19 polymorphisms and cancer susceptibility: A PRISMA-compliant meta-analysis and bioinformatics prediction.

Authors:  Wei Li; Xia Jiang; Xiaojing Jin; Weitao Yan; Ying Liu; Dongyun Li; Zengren Zhao
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.